BeOne Medicines Ltd.
BeOne Medicines is an integrated biopharmaceutical company that discovers, develops, manufactures and commercializes cancer medicines for patients worldwide. Its business includes a hematology portfolio led by BRUKINSA, alongside sonrotoclax and a BTK degrader in development, and a solid tumor portfolio led by the anti-PD-1 antibody TEVIMBRA. It also commercializes medicines licensed from other companies, including products for cancer treatment in China. BeOne sells its own medicines and earns income from commercializing licensed products and from collaborations. It has commercial capabilities in the U.S., EU and China, and sells products in over 60 markets. The company is incorporated in Switzerland, with operations primarily conducted through subsidiaries in the U.S., China, the UK and Australia. Its headquarters are in Basel.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
BeOne Medicines (ONC) reported Q3 earnings with 33% product revenue growth to $1.9B, operating income up 157% to $419M, and net income at $385M. BRUKINSA sales hit $1.4B, up 34%, with strong global demand. The company highlighted progress in hematology and solid tumor pipelines, including advanced clinical trials and potential new indications.
Morgan Stanley analyst Sean Laaman set a $476 price target for ONC. 11 analysts have issued targets in the last 6 months, with a median of $446. ONC insiders sold 170 times in the past 6 months, and 196 institutional investors added shares while 115 decreased positions.
Ball Titus B. (Principal Accounting Officer) sold 1,559 shares of BeOne Medicines Ltd. (ONC) at an average of $405.57 ($405.55–$406.34, $0.63M total) across 2 trades on 2026-11-06.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BEIGF (BeOne Medicines Ltd.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent BEIGF coverage spans earnings, financial news and insider activity.
In the last 30 days, BEIGF insiders filed 15 SEC Form 4 transactions — no purchases and 15 sales ($12.3M). The most active reporter was Wang Xiaodong with 11 filings. 87% of those filings were made under pre-arranged Rule 10b5-1 plans.
BeOne Medicines (ONC) reported Q3 earnings with 33% product revenue growth to $1.9B, operating income up 157% to $419M, and net income at $385M. BRUKINSA sales hit $1.4B, up 34%, with strong global demand. The company highlighted progress in hematology and solid tumor pipelines, including advanced clinical trials and potential new indications.
Morgan Stanley analyst Sean Laaman set a $476 price target for ONC. 11 analysts have issued targets in the last 6 months, with a median of $446. ONC insiders sold 170 times in the past 6 months, and 196 institutional investors added shares while 115 decreased positions.
Ball Titus B. (Principal Accounting Officer) sold 1,559 shares of BeOne Medicines Ltd. (ONC) at an average of $405.57 ($405.55–$406.34, $0.63M total) across 2 trades on 2026-11-06.
Guidance lift suggests stronger sales momentum, likely supporting the stock.
BeOne Medicines reported Q3 2026 revenue of $1.89 billion, up 34% YoY, with GAAP earnings of $3.28 per ADS. The company raised its full-year revenue guidance to $6.9B-$7.0B. Key products BRUKINSA and TEVIMBRA saw regulatory progress, and the company announced new collaborations and partnerships.
AlphAI scores every news story that mentions BEIGF with an AI model for sentiment and relevance, and aggregates insider trades from BeOne Medicines Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BeOne Medicines (ONC) reported Q3 earnings with 33% product revenue growth to $1.9B, operating income up 157% to $419M, and net income at $385M. BRUKINSA sales hit $1.4B, up 34%, with strong global demand. The company highlighted progress in hematology and solid tumor pipelines, including advanced clinical trials and potential new indications.
Morgan Stanley analyst Sean Laaman set a $476 price target for ONC. 11 analysts have issued targets in the last 6 months, with a median of $446. ONC insiders sold 170 times in the past 6 months, and 196 institutional investors added shares while 115 decreased positions.
Ball Titus B. (Principal Accounting Officer) sold 1,559 shares of BeOne Medicines Ltd. (ONC) at an average of $405.57 ($405.55–$406.34, $0.63M total) across 2 trades on 2026-11-06.
BeOne Medicines AG (OTCMKTS:BEIGF) raised its 2026 revenue outlook to $6.9B-$7.0B and plans to file tacabrutideg in mid-2027. Q3 2026 sales reached $1.4B, up 34% YoY, with strong U.S. performance. CEO John Oyler highlighted the company's execution and results.
BeOne Medicines reported Q3 2026 revenue of $1.89 billion, up 34% YoY, with GAAP earnings of $3.28 per ADS. The company raised its full-year revenue guidance to $6.9B-$7.0B. Key products BRUKINSA and TEVIMBRA saw regulatory progress, and the company announced new collaborations and partnerships.
BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,
FDA granted Priority Review to BeOne Medicines' (ONC) BRUKINSA (zanubrutinib) in combination with rituximab for treating previously untreated mantle cell lymphoma. The application is based on Phase 3 MANGROVE study data showing a 43% reduction in progression or death risk compared to bendamustine plus rituximab. The company also submitted applications to the EMA and China's NMPA.
Wang Xiaodong sold 31,028 shares of BeOne Medicines Ltd. (ONC) at an average of $362.97 ($355.56–$366.22, $11.26M total) across 11 trades on 2026-10-27 under a Rule 10b5-1 trading plan.
BeOne Medicines presented data at ESMO 2026 on three investigational cancer treatments. GPC3 x 4-1BB bispecific showed 36% ORR in liver cancer, PRMT5 inhibitor demonstrated 25.3% ORR in lung cancer, and CEA-targeting ADC achieved 56% ORR in high-CEA lung cancer. The company plans global trials for these treatments.
BeOne Medicines reported results from its HERIZON-GEA-01 Phase 3 trial, showing median overall survival of 27.0 months for TEVIMBRA plus ZIIHERA and chemotherapy, with a hazard ratio of 0.65. ZIIHERA plus chemotherapy alone showed 22.9 months. The trial met a primary endpoint with a p-value of 0.0088. The study involved 914 patients across 30 countries, with no new safety signals identified.
